Explore
Present and Future of Personalised Medicine for Endocrine Cancers
0 Ungluers have
Faved this Work
Login to Fave
Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 40 times via unglue.it ebook links.
- 40 - pdf (CC BY) at Unglue.it.
Keywords
- adjuvant treatment
- adrenal adenomas
- Adrenal Cortex
- adrenal tumors
- adrenocortical cancer
- aggressive PitNET
- aggressive pituitary adenoma
- aggressive pituitary tumor
- Angiogenesis
- BRAF
- BRAF V600E
- carcinoma
- Cushing’s disease
- differentiated thyroid cancer
- focus group interview
- Gene expression
- hyaluronan synthase 1
- immune checkpoint inhibitors (ICIs)
- information needs and preferences
- intratumoral heterogeneity
- ipilimumab
- ki-67
- lenvatinib
- medicine
- mitotane
- molecular clusters
- multikinase inhibitors
- n/a
- neuroendocrine tumours
- Nivolumab
- osteopontin
- p27
- p53
- Papillary thyroid cancer
- paraganglioma
- personalized medicine
- phaeochromocytoma
- pituitary carcinoma
- predictive marker
- predictors
- prolactinoma
- radioiodine resistance
- RAS mutation
- recurrence
- recurrence free survival
- response to treatment
- RET/PTC rearrangements
- reticulin
- sorafenib
- Survival
- SUV PET/CT
- thyroid tumor
- timing
Links
DOI: 10.3390/books978-3-0365-4329-1Editions